Published in Clin Cancer Res on September 01, 2004
Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow. Cell (2008) 2.84
Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression. Annu Rev Pathol (2011) 0.91
Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve-sheath tumors. BMC Med (2013) 0.88
KITLG is a novel target of miR-34c that is associated with the inhibition of growth and invasion in colorectal cancer cells. J Cell Mol Med (2014) 0.88
Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases. Br J Pharmacol (2014) 0.87
Genetic and functional studies implicate synaptic overgrowth and ring gland cAMP/PKA signaling defects in the Drosophila melanogaster neurofibromatosis-1 growth deficiency. PLoS Genet (2013) 0.83
Nf1-/- Schwann cell-conditioned medium modulates mast cell degranulation by c-Kit-mediated hyperactivation of phosphatidylinositol 3-kinase. Am J Pathol (2010) 0.82
MIA is a potential biomarker for tumour load in neurofibromatosis type 1. BMC Med (2011) 0.79
Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas. Pediatr Blood Cancer (2015) 0.76
Effector T cell subclasses associate with tumor burden in neurofibromatosis type 1 patients. Cancer Immunol Immunother (2016) 0.75
The role of the immune system in neurofibromatosis type 1-associated nervous system tumors. CNS Oncol (2016) 0.75
Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res (2009) 2.74
Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A (2009) 2.47
Oncolytic viral therapies - the clinical experience. Oncogene (2005) 2.30
Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells. Neuro Oncol (2011) 1.80
Depletion of peripheral macrophages and brain microglia increases brain tumor titers of oncolytic viruses. Cancer Res (2007) 1.60
Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation. Neurosurgery (2009) 1.47
Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst (2006) 1.47
Cancer risk in people with epilepsy: the role of antiepileptic drugs. Brain (2004) 1.44
Resection of small plexiform neurofibromas in neurofibromatosis type 1 children. World J Surg Oncol (2005) 1.39
Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev (2005) 1.38
An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep (2013) 1.35
Screening 500 unselected neurofibromatosis 1 patients for deletions of the NF1 gene. Hum Mutat (2004) 1.34
Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. Proc Natl Acad Sci U S A (2013) 1.33
Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging (2006) 1.32
Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol (2009) 1.28
Histone deacetylase controls adult stem cell aging by balancing the expression of polycomb genes and jumonji domain containing 3. Cell Mol Life Sci (2010) 1.25
Human embryonic stem cell lines and their use in international research. Stem Cells (2010) 1.25
Mesenchymal stem cells for cardiac cell therapy. Hum Gene Ther (2011) 1.24
Current state of human embryonic stem cell research: an overview of cell lines and their use in experimental work. Stem Cells (2006) 1.21
Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells. J Natl Cancer Inst (2011) 1.19
Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Res (2005) 1.19
Size exclusion limits and lateral heterogeneity of the stomatal foliar uptake pathway for aqueous solutes and water-suspended nanoparticles. Physiol Plant (2008) 1.19
Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors. J Neurooncol (2006) 1.18
Protein tyrosine phosphatase receptor type Z is inactivated by ligand-induced oligomerization. FEBS Lett (2006) 1.16
Genetic and phenotypic characterization of tumor cells derived from malignant peripheral nerve sheath tumors of neurofibromatosis type 1 patients. Neurobiol Dis (2004) 1.15
Midkine plays a protective role against cardiac ischemia/reperfusion injury through a reduction of apoptotic reaction. Circulation (2006) 1.15
Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. Neuro Oncol (2012) 1.14
Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases. BMC Biotechnol (2006) 1.12
alpha4beta1- and alpha6beta1-integrins are functional receptors for midkine, a heparin-binding growth factor. J Cell Sci (2004) 1.12
Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis (2005) 1.11
Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects. Mol Ther (2008) 1.11
Neurodegeneration in newborn rats following propofol and sevoflurane anesthesia. Neurotox Res (2009) 1.11
Psychosurgery: past, present, and future. Brain Res Brain Res Rev (2005) 1.10
Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol Ther (2006) 1.09
Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors. Clin Cancer Res (2006) 1.09
Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide. Cancer Res (2007) 1.08
Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. Int J Oncol (2005) 1.08
MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. Neoplasia (2007) 1.07
Immunohistochemical evaluation of solid pseudopapillary tumors of the pancreas: the expression pattern of CD99 is highly unique. Cancer Lett (2011) 1.07
Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors. Acta Neuropathol (2003) 1.07
Enhanced antitumor efficacy of low-dose Etoposide with oncolytic herpes simplex virus in human glioblastoma stem cell xenografts. Clin Cancer Res (2011) 1.06
A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. Clin Cancer Res (2011) 1.06
Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma. Mol Ther (2011) 1.04
Subclassification of nerve sheath tumors by gene expression profiling. Brain Pathol (2004) 1.03
Induction of differentiation and suppression of malignant phenotype of human neuroblastoma BE(2)-C cells by valproic acid: enhancement by combination with interferon-alpha. Int J Oncol (2002) 1.02
Differences in supratentorial damage of white matter in pediatric survivors of posterior fossa tumors with and without adjuvant treatment as detected by magnetic resonance diffusion tensor imaging. Int J Radiat Oncol Biol Phys (2009) 0.99
Subtotal and total resection of superficial plexiform neurofibromas of face and neck: four case reports. J Craniomaxillofac Surg (2005) 0.99
Preliminary evaluation of the CellFinder literature curation pipeline for gene expression in kidney cells and anatomical parts. Database (Oxford) (2013) 0.99
Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma. Cancer Res (2003) 0.99
Midkine in plasma as a novel breast cancer marker. Cancer Sci (2009) 0.98
Preoperative serum midkine concentration is a prognostic marker for esophageal squamous cell carcinoma. Cancer Sci (2003) 0.98
Effects of complementary eurythmy therapy on heart rate variability. Complement Ther Med (2008) 0.98
Valproic acid and interferon-alpha synergistically inhibit neuroblastoma cell growth in vitro and in vivo. Int J Oncol (2004) 0.97
Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses. Cancer Res (2007) 0.97
Risk for late-onset blood-culture proven sepsis in very-low-birth weight infants born small for gestational age: a large multicenter study from the German Neonatal Network. Pediatr Infect Dis J (2014) 0.97
Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. Neoplasia (2013) 0.96
Evaluation of intratumoural heterogeneity on ¹⁸F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1. Eur J Nucl Med Mol Imaging (2012) 0.96
Concerted regulation of CD34 and CD105 accompanies mesenchymal stromal cell derivation from human adventitial stromal cell. Stem Cells Dev (2012) 0.96
Epigenetic inactivation of the tumor suppressor gene RIZ1 in hepatocellular carcinoma involves both DNA methylation and histone modifications. J Hepatol (2010) 0.95
Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication. Cancer Res (2010) 0.95
Hypoxia enhances the replication of oncolytic herpes simplex virus. Mol Ther (2008) 0.95
Glycosaminoglycan structures required for strong binding to midkine, a heparin-binding growth factor. Glycobiology (2002) 0.94
Constitutional NF1 mutations in neurofibromatosis 1 patients with malignant peripheral nerve sheath tumors. Hum Mutat (2003) 0.94
The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. J Neurooncol (2008) 0.94
Systemically administered human bone marrow-derived mesenchymal stem home into peripheral organs but do not induce neuroprotective effects in the MCAo-mouse model for cerebral ischemia. Neurosci Lett (2012) 0.93
Receptor-type protein tyrosine phosphatase zeta as a component of the signaling receptor complex for midkine-dependent survival of embryonic neurons. Neurosci Res (2003) 0.93
Interleukin-1beta, interleukin-18, and interferon-gamma expression in the cerebrospinal fluid of premature infants with posthemorrhagic hydrocephalus--markers of white matter damage? Pediatr Res (2007) 0.93
Mesenchymal stromal cells but not cardiac fibroblasts exert beneficial systemic immunomodulatory effects in experimental myocarditis. PLoS One (2012) 0.92
Loss of heterozygosity and methylation of multiple tumor suppressor genes on chromosome 3 in hepatocellular carcinoma. J Gastroenterol (2012) 0.92
Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung. Clin Cancer Res (2006) 0.92
Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics. Clin Cancer Res (2007) 0.92
Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector. Cancer Res (2006) 0.92
Incidence of bisphosphonate-related osteonecrosis of the jaw in consideration of primary diseases and concomitant therapies. Anticancer Res (2013) 0.91
Oncomodulation by human cytomegalovirus: novel clinical findings open new roads. Med Microbiol Immunol (2010) 0.91
Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Clin Nucl Med (2013) 0.91
Dose-dependent effects of erythropoietin in propofol anesthetized neonatal rats. Brain Res (2010) 0.91
Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells. Clin Cancer Res (2008) 0.91
Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis. Neoplasia (2005) 0.91
CyclinD1, a prominent prognostic marker for endometrial diseases. Diagn Pathol (2013) 0.91
Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors. J Virol (2012) 0.90
High levels of urinary midkine in various cancer patients. Biochem Biophys Res Commun (2003) 0.90
Isolation and characterization of fenamiphos degrading bacteria. Biodegradation (2010) 0.90
Bacterial pore-forming cytolysins induce neuronal damage in a rat model of neonatal meningitis. J Infect Dis (2010) 0.89
Germline and somatic NF1 gene mutations in plexiform neurofibromas. Hum Mutat (2008) 0.89
Podoplanin and CD34 in peripheral nerve sheath tumours: focus on neurofibromatosis 1-associated atypical neurofibroma. J Neurooncol (2010) 0.89
Midkine prevents ventricular remodeling and improves long-term survival after myocardial infarction. Am J Physiol Heart Circ Physiol (2008) 0.89
Efficacy and selectivity of nilotinib on NF1-associated tumors in vitro. J Neurooncol (2013) 0.89
Expression level of neural cell adhesion molecule (NCAM) inversely correlates with the ability of neuroblastoma cells to adhere to endothelium in vitro. Cell Commun Adhes (2003) 0.88
Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells. Stem Cells Transl Med (2012) 0.88
Presymptomatic diagnosis for children of sporadic neurofibromatosis 2 patients: a method based on tumor analysis. Genet Med (2002) 0.88
Oral Langerhans cell histiocytosis. J Craniomaxillofac Surg (2002) 0.88
Ral overactivation in malignant peripheral nerve sheath tumors. Mol Cell Biol (2009) 0.88
Genetic determinants of hearing loss associated with vestibular schwannomas. Otol Neurotol (2009) 0.88
Serum biomarkers for neurofibromatosis type 1 and early detection of malignant peripheral nerve-sheath tumors. BMC Med (2013) 0.88